share_log

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder

武田吹捧Hyqvia治療罕見神經炎性疾病的令人鼓舞的數據
Benzinga Real-time News ·  2022/07/21 10:36
  • Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) met its primary endpoint. 
  • CIPD is a rare chronic autoimmune disease affecting the peripheral nervous system, resulting in progressive symmetric weakness and impaired sensory function in the arms and legs.
  • Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment. 
  • Also Read: Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years.
  • Analyses from ADVANCE-1 are ongoing, and the company anticipates disclosing additional data in an upcoming medical forum.
  • HYQVIA showed a favorable safety profile in topline analyses, further supporting its use as maintenance therapy for CIDP. 
  • Of the 62 patients treated with HYQVIA, most treatment-related adverse events were reported as mild or moderate. No new safety risks were reported with HYQVIA. 
  • The safety profile of HYQVIA in CIDP will be further supported by data from the ongoing ADVANCE-3 trial, an extension study with up to six years of follow-up data on some participants.
  • Price Action: TAK shares are up 0.52% at $14.56 during the market session on the last check Thursday.
  • 武田製藥株式會社Hyqvia維持治療慢性炎症性脱髓鞘多神經根神經病(CIDP)的(紐約證券交易所市場代碼：TAK)3期試驗(Advance-1)達到了其主要終點。
  • CIPD是一種罕見的慢性自身免疫性疾病，影響周圍神經系統，導致進行性對稱性虛弱和手臂和腿部感覺功能受損。
  • TOPLINE數據顯示，HyQvia減少了神經肌肉殘疾和損傷的復發。
  • 另請閲讀： 武田的遺傳性血管水腫治療可防止12歲以下兒童發作.
  • 來自Advance-1的分析正在進行中，該公司預計將在即將到來的醫學論壇上披露更多數據。
  • HyQvia在背線分析中顯示出良好的安全性，進一步支持將其用作CIDP的維持療法。
  • 在接受HyQvia治療的62名患者中，據報道，大多數與治療相關的不良反應為輕度或中度。沒有關於HyQvia的新安全風險的報告。
  • HyQvia在CIDP中的安全性將得到正在進行的Advance-3試驗數據的進一步支持，該試驗是一項擴展研究，對一些參與者進行了長達6年的隨訪數據。
  • 價格行動：週四尾盤，德意志銀行股價上漲0.52%，至14.56美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論